利妥昔单抗治疗伴 Vogt-小柳原田病的难治性慢性复发性葡萄膜炎的疗效。
Efficacy of B Cell Depletion Therapy with Rituximab in Refractory Chronic Recurrent Uveitis Associated with Vogt-Koyanagi-Harada Disease.
机构信息
Department of Ophthalmology, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Dr. Nasser Al-Rashid Research Chair in Ophthalmology, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
出版信息
Ocul Immunol Inflamm. 2022 Apr 3;30(3):750-757. doi: 10.1080/09273948.2020.1820531. Epub 2020 Sep 29.
PURPOSE
To evaluate the efficacy of B cell depletion therapy with the chimeric mouse/human anti-CD20 monoclonal antibody rituximab for refractory chronic recurrent granulomatous uveitis associated with Vogt-Koyanagi-Harada (VKH) disease.
METHODS
Retrospective study of 9 patients (18 eyes) who failed to respond to conventional combination immunosuppressive therapy.
RESULTS
All the patients received 3 rituximab infusions. The follow-up period after initiation of rituximab therapy ranged from 9 to 36 months (mean ±SD, 19.2 ± 10.1). All patients achieved remission and visual acuity significantly improved ( < .001). Rituximab provided corticosteroid-sparing effect along with control of inflammation. No rituximab-related complications were observed.
CONCLUSIONS
Rituximab is effective for the treatment of refractory chronic recurrent granulomatous uveitis associated with VKH disease.
目的
评估嵌合鼠/人抗 CD20 单克隆抗体利妥昔单抗（rituximab）用于治疗 B 细胞耗竭疗法对伴有 Vogt-小柳原田（Vogt-Koyanagi-Harada，VKH）病的难治性慢性复发性肉芽肿性葡萄膜炎的疗效。
方法
对 9 例（18 只眼）常规联合免疫抑制治疗无效的患者进行回顾性研究。
结果
所有患者均接受 3 次利妥昔单抗输注。利妥昔单抗治疗开始后的随访时间为 9 至 36 个月（平均值 ±标准差，19.2 ± 10.1）。所有患者均达到缓解，视力明显改善（ < 0.001）。利妥昔单抗具有减轻皮质类固醇用量和控制炎症的作用。未观察到与利妥昔单抗相关的并发症。
结论
利妥昔单抗治疗伴有 VKH 病的难治性慢性复发性肉芽肿性葡萄膜炎有效。
Zotero 插件